Identification

Name
Pipecuronium
Accession Number
DB01338
Type
Small Molecule
Groups
Approved
Description

Pipecuronium is a piperazinyl androstane derivative which is a non-depolarizing neuromuscular blocking agent.

Structure
Thumb
Synonyms
  • Pipecurium
  • Pipecuronium
Product Ingredients
IngredientUNIICASInChI Key
Pipecuronium bromideR6ZTY81RE152212-02-9TXWBOBJCRVVBJF-YTGGZNJNSA-L
International/Other Brands
Arduan
Categories
UNII
1N3O74HM92
CAS number
68399-58-6
Weight
Average: 602.8912
Monoisotopic: 602.477106492
Chemical Formula
C35H62N4O4
InChI Key
OWWLUIWOFHMHOQ-XGHATYIMSA-N
InChI
InChI=1S/C35H62N4O4/c1-24(40)42-32-21-26-9-10-27-28(35(26,4)23-31(32)37-15-19-39(7,8)20-16-37)11-12-34(3)29(27)22-30(33(34)43-25(2)41)36-13-17-38(5,6)18-14-36/h26-33H,9-23H2,1-8H3/q+2/t26-,27+,28-,29-,30-,31-,32-,33-,34-,35-/m0/s1
IUPAC Name
4-[(1S,2S,4S,5S,7S,10R,11S,13S,14R,15S)-5,14-bis(acetyloxy)-13-(4,4-dimethylpiperazin-4-ium-1-yl)-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-4-yl]-1,1-dimethylpiperazin-1-ium
SMILES
[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CC[N+](C)(C)CC1)N1CC[N+](C)(C)CC1

Pharmacology

Indication

Used as a muscle relaxant during anesthesia and surgical procedures.

Pharmacodynamics

Pipecuronium is a nondepolarizing neuromuscular blocking agent. Neuromuscular blocking agents produce skeletal muscle paralysis by blocking neural transmission at the myoneural junction. The paralysis is selective initially and usually appears in the following muscles consecutively: levator muscles of eyelids, muscles of mastication, limb muscles, abdominal muscles, muscles of the glottis, and finally, the intercostal muscles and the diaphragm. Neuromuscular blocking agents have no clinically significant effect on consciousness or the pain threshold.

Mechanism of action

Nondepolarizing neuromuscular blocking agents inhibit neuromuscular transmission by competing with acetylcholine for the cholinergic receptors of the motor end plate, thereby reducing the response of the end plate to acetylcholine. This type of neuromuscular block is usually antagonized by anticholinesterase agents.

TargetActionsOrganism
ANeuronal acetylcholine receptor subunit alpha-2
antagonist
Human
UMuscarinic acetylcholine receptor M2
antagonist
Human
UMuscarinic acetylcholine receptor M3
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life

Distribution Normal renal function: 6.22 (range, 1.34 to 10.66) minutes. Renal function impairment: 4.33 (range, 1.69 to 6.17) minutes. Elimination Normal renal function: 1.7 (range, 0.9 to 2.7) hours. The elimination half-life is not altered by hypothermia and bypass. Renal function impairment: 4 (range, 2 to 8.2) hours. [PharmGKB]

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with 1,10-Phenanthroline.Experimental
AcetyldigitoxinPipecuronium may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
AcetyldigoxinPipecuronium may increase the arrhythmogenic activities of Acetyldigoxin.Experimental
AclidiniumPipecuronium may increase the anticholinergic activities of Aclidinium.Approved
AgmatineAgmatine may increase the neuromuscular blocking activities of Pipecuronium.Experimental, Investigational
AlcuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Alcuronium.Experimental
AlfentanilThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Alphaprodine.Illicit
AmbenoniumThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Ambenonium.Approved
AmikacinThe therapeutic efficacy of Pipecuronium can be increased when used in combination with Amikacin.Approved, Investigational, Vet Approved
AmiodaroneAmiodarone may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational
AmlodipineAmlodipine may increase the neuromuscular blocking activities of Pipecuronium.Approved
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Pipecuronium.Approved
ApramycinApramycin may increase the respiratory depressant activities of Pipecuronium.Experimental, Vet Approved
AranidipineAranidipine may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational
ArbekacinArbekacin may increase the respiratory depressant activities of Pipecuronium.Approved, Investigational
AtracuriumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Atracurium.Approved, Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Pipecuronium.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Pipecuronium.Approved, Vet Approved
AzelnidipineAzelnidipine may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational
AzosemideAzosemide may decrease the neuromuscular blocking activities of Pipecuronium.Investigational
BarnidipineBarnidipine may increase the neuromuscular blocking activities of Pipecuronium.Approved
Beclomethasone dipropionateThe risk or severity of myopathy and weakness can be increased when Pipecuronium is combined with Beclomethasone dipropionate.Approved, Investigational
BekanamycinBekanamycin may increase the respiratory depressant activities of Pipecuronium.Experimental
BenactyzineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Benactyzine.Withdrawn
BencyclaneBencyclane may increase the neuromuscular blocking activities of Pipecuronium.Experimental
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Pipecuronium.Approved
BenidipineBenidipine may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Pipecuronium.Approved
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Pipecuronium.Approved, Illicit
BenzthiazideThe serum concentration of Benzthiazide can be increased when it is combined with Pipecuronium.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Pipecuronium.Approved
BepridilBepridil may increase the neuromuscular blocking activities of Pipecuronium.Approved, Withdrawn
BezitramideThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Bezitramide.Experimental, Illicit, Withdrawn
BioallethrinBioallethrin may increase the neuromuscular blocking activities of Pipecuronium.Approved, Experimental
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Pipecuronium.Approved, Investigational
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Pipecuronium.Approved
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Pipecuronium.Experimental
Botulinum Toxin Type ABotulinum Toxin Type A may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational
Botulinum Toxin Type BPipecuronium may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Pipecuronium.Approved
BudesonideThe risk or severity of myopathy and weakness can be increased when Pipecuronium is combined with Budesonide.Approved
BumetanideBumetanide may decrease the neuromuscular blocking activities of Pipecuronium.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Pipecuronium.Approved
ButorphanolThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Butorphanol.Approved, Illicit, Vet Approved
ButylscopolamineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Butylscopolamine.Approved, Investigational, Vet Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Pipecuronium.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Pipecuronium.Approved, Investigational
CarboxyamidotriazoleCarboxyamidotriazole may increase the neuromuscular blocking activities of Pipecuronium.Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Carfentanil.Illicit, Investigational, Vet Approved
CaroverineCaroverine may increase the neuromuscular blocking activities of Pipecuronium.Experimental
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Pipecuronium.Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Pipecuronium.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pipecuronium.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Chlorphenoxamine.Withdrawn
ChlortetracyclineChlortetracycline may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational, Vet Approved
ChlorthalidoneChlorthalidone may decrease the neuromuscular blocking activities of Pipecuronium.Approved
CilnidipineCilnidipine may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational
CimetropiumPipecuronium may increase the anticholinergic activities of Cimetropium.Experimental, Investigational
CinnarizineCinnarizine may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Pipecuronium.Approved, Investigational
ClevidipineClevidipine may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational
ClindamycinThe therapeutic efficacy of Pipecuronium can be increased when used in combination with Clindamycin.Approved, Vet Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Pipecuronium.Approved, Illicit
ColistimethateColistimethate may increase the neuromuscular blocking activities of Pipecuronium.Approved, Vet Approved
CoumaphosThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Coumaphos.Vet Approved
CyclandelateCyclandelate may increase the neuromuscular blocking activities of Pipecuronium.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pipecuronium.Approved
CyclopenthiazideThe serum concentration of Cyclopenthiazide can be increased when it is combined with Pipecuronium.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Pipecuronium.Approved
CyclosporineThe therapeutic efficacy of Pipecuronium can be increased when used in combination with Cyclosporine.Approved, Investigational, Vet Approved
CymarinPipecuronium may increase the arrhythmogenic activities of Cymarin.Experimental
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Pipecuronium.Approved, Investigational
DarodipineDarodipine may increase the neuromuscular blocking activities of Pipecuronium.Experimental
DecamethoniumThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Decamethonium.Approved
DemecariumThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Demecarium.Approved
DemeclocyclineDemeclocycline may increase the neuromuscular blocking activities of Pipecuronium.Approved
DeslanosidePipecuronium may increase the arrhythmogenic activities of Deslanoside.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Pipecuronium.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Desvenlafaxine.Approved, Investigational
DexamethasoneThe risk or severity of myopathy and weakness can be increased when Pipecuronium is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pipecuronium.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Pipecuronium.Withdrawn
DexniguldipineDexniguldipine may increase the neuromuscular blocking activities of Pipecuronium.Experimental
DextromethorphanThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DexverapamilDexverapamil may increase the neuromuscular blocking activities of Pipecuronium.Experimental
DezocineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Dezocine.Approved, Investigational
DibekacinDibekacin may increase the respiratory depressant activities of Pipecuronium.Experimental
DichlorvosThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Pipecuronium.Approved
DigitoxinPipecuronium may increase the arrhythmogenic activities of Digitoxin.Approved, Investigational
DigoxinPipecuronium may increase the arrhythmogenic activities of Digoxin.Approved
Digoxin Immune Fab (Ovine)Pipecuronium may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Dihydromorphine.Experimental, Illicit
DihydrostreptomycinDihydrostreptomycin may increase the respiratory depressant activities of Pipecuronium.Investigational, Vet Approved
DiltiazemDiltiazem may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Pipecuronium.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Pipecuronium.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Diphenoxylate.Approved, Illicit
DipivefrinThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Dipivefrin.Approved
DistigmineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Distigmine.Experimental
DocusateThe therapeutic efficacy of Docusate can be decreased when used in combination with Pipecuronium.Approved
DonepezilThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Donepezil.Approved
DotarizineDotarizine may increase the neuromuscular blocking activities of Pipecuronium.Investigational
DoxycyclineDoxycycline may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Pipecuronium.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Pipecuronium is combined with DPDPE.Experimental
DronabinolPipecuronium may increase the tachycardic activities of Dronabinol.Approved, Illicit
EchothiophateThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Echothiophate.Approved
EdrophoniumThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Edrophonium.Approved
EfonidipineEfonidipine may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational
EluxadolinePipecuronium may increase the constipating activities of Eluxadoline.Approved, Investigational
EmeproniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Emepronium.Experimental
EmopamilEmopamil may increase the neuromuscular blocking activities of Pipecuronium.Experimental
EperisoneEperisone may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational
EpitizideThe serum concentration of Epitizide can be increased when it is combined with Pipecuronium.Experimental
Etacrynic acidEtacrynic acid may decrease the neuromuscular blocking activities of Pipecuronium.Approved, Investigational
EtanautineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Etanautine.Experimental
EthanolPipecuronium may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Pipecuronium.Approved
EthosuximideEthosuximide may increase the neuromuscular blocking activities of Pipecuronium.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Ethylmorphine.Approved, Illicit
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Pipecuronium.Approved
EtorphineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Etybenzatropine.Experimental
FelodipineFelodipine may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational
FendilineFendiline may increase the neuromuscular blocking activities of Pipecuronium.Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Pipecuronium.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Fesoterodine.Approved
Fish oilFish oil may increase the neuromuscular blocking activities of Pipecuronium.Approved, Nutraceutical
FlavoxateThe risk or severity of adverse effects can be increased when Flavoxate is combined with Pipecuronium.Approved
FlunarizineFlunarizine may increase the neuromuscular blocking activities of Pipecuronium.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Fluoxetine.Approved, Vet Approved
FluspirileneFluspirilene may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Pipecuronium.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Fluvoxamine.Approved, Investigational
FramycetinFramycetin may increase the respiratory depressant activities of Pipecuronium.Approved
FurosemideFurosemide may decrease the neuromuscular blocking activities of Pipecuronium.Approved, Vet Approved
GabapentinGabapentin may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational
GalantamineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Galantamine.Approved
GallamineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Gallamine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Pipecuronium.Approved
GallopamilGallopamil may increase the neuromuscular blocking activities of Pipecuronium.Investigational
GeneticinGeneticin may increase the respiratory depressant activities of Pipecuronium.Experimental
GentamicinGentamicin may increase the respiratory depressant activities of Pipecuronium.Approved, Vet Approved
GENTAMICIN C1AGENTAMICIN C1A may increase the respiratory depressant activities of Pipecuronium.Experimental
Ginkgo bilobaThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Ginkgo biloba.Approved, Investigational, Nutraceutical
GitoformatePipecuronium may increase the arrhythmogenic activities of Gitoformate.Experimental
Glucagon recombinantThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Glucagon recombinant.Approved
GlycerinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Pipecuronium.Approved, Investigational
GlycopyrroniumPipecuronium may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Pipecuronium.Approved, Investigational
HeroinThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Heroin.Approved, Illicit, Investigational
HomatropineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Homatropine.Approved
Huperzine AThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Huperzine A.Approved, Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Pipecuronium.Approved, Vet Approved
HydrocodonePipecuronium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe risk or severity of myopathy and weakness can be increased when Pipecuronium is combined with Hydrocortisone.Approved, Vet Approved
Hydrocortisone acetateThe risk or severity of myopathy and weakness can be increased when Pipecuronium is combined with Hydrocortisone acetate.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of myopathy and weakness can be increased when Pipecuronium is combined with Hydrocortisone butyrate.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may decrease the neuromuscular blocking activities of Pipecuronium.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Hydromorphone.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pipecuronium.Approved
Hygromycin BHygromycin B may increase the respiratory depressant activities of Pipecuronium.Vet Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Pipecuronium.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Pipecuronium.Approved
IpidacrineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Ipidacrine.Experimental
IpratropiumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Ipratropium.Approved
IsepamicinIsepamicin may increase the respiratory depressant activities of Pipecuronium.Experimental
IsoflurophateThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Isoflurophate.Approved, Investigational, Withdrawn
IsradipineIsradipine may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Pipecuronium.Investigational
KanamycinKanamycin may increase the respiratory depressant activities of Pipecuronium.Approved, Investigational, Vet Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Ketobemidone.Approved, Investigational
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Pipecuronium.Approved
LacidipineLacidipine may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational
LactuloseThe therapeutic efficacy of Lactulose can be decreased when used in combination with Pipecuronium.Approved
LamotrigineLamotrigine may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational
Lanatoside CPipecuronium may increase the arrhythmogenic activities of Lanatoside C.Experimental
LercanidipineLercanidipine may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational
LevetiracetamLevetiracetam may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Pipecuronium.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Levomethadyl Acetate.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Levorphanol.Approved
LidoflazineLidoflazine may increase the neuromuscular blocking activities of Pipecuronium.Experimental
LincomycinLincomycin may increase the neuromuscular blocking activities of Pipecuronium.Approved, Vet Approved
Lithium cationLithium may increase the neuromuscular blocking activities of Pipecuronium.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Lofentanil.Illicit
LomerizineLomerizine may increase the neuromuscular blocking activities of Pipecuronium.Experimental
LoperamideLoperamide may increase the neuromuscular blocking activities of Pipecuronium.Approved
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Pipecuronium.Approved, Investigational
LorpiprazoleThe therapeutic efficacy of Pipecuronium can be increased when used in combination with Lorpiprazole.Approved
Magnesium carbonateThe therapeutic efficacy of Pipecuronium can be increased when used in combination with Magnesium carbonate.Approved, Investigational
Magnesium citrateThe therapeutic efficacy of Pipecuronium can be increased when used in combination with Magnesium citrate.Approved
Magnesium hydroxideThe therapeutic efficacy of Pipecuronium can be increased when used in combination with Magnesium hydroxide.Approved, Investigational
Magnesium oxideMagnesium oxide may increase the neuromuscular blocking activities of Pipecuronium.Approved
Magnesium salicylateMagnesium salicylate may increase the neuromuscular blocking activities of Pipecuronium.Approved
Magnesium sulfateThe therapeutic efficacy of Pipecuronium can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe therapeutic efficacy of Pipecuronium can be increased when used in combination with Magnesium Trisilicate.Approved
MalathionThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Malathion.Approved, Investigational
ManidipineManidipine may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational
MazaticolThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Mazaticol.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Pipecuronium.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Pipecuronium.Approved
MefloquineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Mefloquine.Approved, Investigational
MemantineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Memantine.Approved, Investigational
MentholMenthol may increase the neuromuscular blocking activities of Pipecuronium.Approved
MeptazinolThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Meptazinol.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Methadyl Acetate.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Pipecuronium.Approved, Investigational
MethscopolamineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Methscopolamine.Approved
MethsuximideMethsuximide may increase the neuromuscular blocking activities of Pipecuronium.Approved
MethyclothiazideMethyclothiazide may decrease the neuromuscular blocking activities of Pipecuronium.Approved
MethylprednisoloneThe risk or severity of myopathy and weakness can be increased when Pipecuronium is combined with Methylprednisolone.Approved, Vet Approved
Methylscopolamine bromideThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Methylscopolamine bromide.Approved
MetildigoxinPipecuronium may increase the arrhythmogenic activities of Metildigoxin.Experimental
MetixeneThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Metixene.Approved
MetoclopramideThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Pipecuronium.Approved
MianserinMianserin may increase the anticholinergic activities of Pipecuronium.Approved, Investigational
MibefradilMibefradil may increase the neuromuscular blocking activities of Pipecuronium.Investigational, Withdrawn
MicronomicinMicronomicin may increase the respiratory depressant activities of Pipecuronium.Experimental
MinaprineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Minaprine.Approved
Mineral oilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Pipecuronium.Approved, Vet Approved
MinocyclineMinocycline may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational
MirabegronThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Mirabegron.Approved
MorphineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Morphine.Approved, Investigational
NabilonePipecuronium may increase the tachycardic activities of Nabilone.Approved, Investigational
NaftopidilNaftopidil may increase the neuromuscular blocking activities of Pipecuronium.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Nalbuphine.Approved
NeamineNeamine may increase the respiratory depressant activities of Pipecuronium.Experimental
NeomycinThe therapeutic efficacy of Pipecuronium can be increased when used in combination with Neomycin.Approved, Vet Approved
NeostigmineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NetilmicinNetilmicin may increase the respiratory depressant activities of Pipecuronium.Approved, Investigational
NicardipineNicardipine may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational
NicomorphineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Nicomorphine.Experimental
NifedipineNifedipine may increase the neuromuscular blocking activities of Pipecuronium.Approved
NiguldipineNiguldipine may increase the neuromuscular blocking activities of Pipecuronium.Experimental
NiludipineNiludipine may increase the neuromuscular blocking activities of Pipecuronium.Experimental
NilvadipineNilvadipine may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational
NimesulideNimesulide may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational
NisoldipineNisoldipine may increase the neuromuscular blocking activities of Pipecuronium.Approved
NitrendipineNitrendipine may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Normethadone.Approved, Illicit
NylidrinNylidrin may increase the neuromuscular blocking activities of Pipecuronium.Approved
OleandrinPipecuronium may increase the arrhythmogenic activities of Oleandrin.Experimental, Investigational
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Pipecuronium.Approved
OpiumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Opium.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Pipecuronium.Approved
OtiloniumOtilonium may increase the neuromuscular blocking activities of Pipecuronium.Experimental, Investigational
OuabainPipecuronium may increase the arrhythmogenic activities of Ouabain.Approved
OxitropiumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Oxitropium.Investigational
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Pipecuronium.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pipecuronium.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Pipecuronium.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Pipecuronium.Approved
OxytetracyclineOxytetracycline may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational, Vet Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Pipecuronium.Approved
ParaoxonThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Paraoxon.Experimental
ParomomycinThe therapeutic efficacy of Pipecuronium can be increased when used in combination with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Paroxetine.Approved, Investigational
PenfluridolPenfluridol may increase the neuromuscular blocking activities of Pipecuronium.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Pentazocine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Pipecuronium.Approved
PeruvosidePipecuronium may increase the arrhythmogenic activities of Peruvoside.Experimental
PethidineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Phenazocine.Experimental
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Pipecuronium.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Pipecuronium.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Phenoperidine.Experimental
PhysostigmineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Physostigmine.Approved, Investigational
PinaveriumPinaverium may increase the neuromuscular blocking activities of Pipecuronium.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Pipecuronium.Approved
PiretanidePiretanide may decrease the neuromuscular blocking activities of Pipecuronium.Approved
PiritramideThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Piritramide.Approved, Investigational
PirlimycinPirlimycin may increase the neuromuscular blocking activities of Pipecuronium.Vet Approved
PlazomicinPlazomicin may increase the respiratory depressant activities of Pipecuronium.Approved, Investigational
Polymyxin B SulfateThe therapeutic efficacy of Pipecuronium can be increased when used in combination with Polymyxin B Sulfate.Approved, Vet Approved
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Pipecuronium.Approved
Potassium ChlorideThe risk or severity of gastrointestinal ulceration can be increased when Pipecuronium is combined with Potassium Chloride.Approved, Withdrawn
PramipexolePipecuronium may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintidePramlintide may increase the anticholinergic activities of Pipecuronium.Approved, Investigational
PrednisoloneThe risk or severity of myopathy and weakness can be increased when Pipecuronium is combined with Prednisolone.Approved, Vet Approved
PregabalinThe therapeutic efficacy of Pipecuronium can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrenylaminePrenylamine may increase the neuromuscular blocking activities of Pipecuronium.Withdrawn
ProcainamideProcainamide may increase the neuromuscular blocking activities of Pipecuronium.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pipecuronium.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Pipecuronium.Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Pipecuronium.Approved, Investigational
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Pipecuronium.Approved
PropiverineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Propiverine.Approved, Investigational
ProscillaridinPipecuronium may increase the arrhythmogenic activities of Proscillaridin.Experimental
PseudoephedrineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Pseudoephedrine.Approved
PuromycinPuromycin may increase the respiratory depressant activities of Pipecuronium.Experimental
PyrantelThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Pyrantel.Approved, Vet Approved
PyridostigmineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Pyridostigmine.Approved, Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Pipecuronium.Approved
QuinethazoneQuinethazone may decrease the neuromuscular blocking activities of Pipecuronium.Approved
QuinidineQuinidine may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational
QuinineQuinine may increase the neuromuscular blocking activities of Pipecuronium.Approved
RamosetronPipecuronium may increase the constipating activities of Ramosetron.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Remifentanil.Approved
RibostamycinRibostamycin may increase the respiratory depressant activities of Pipecuronium.Approved, Investigational
RivastigmineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Rivastigmine.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Rizatriptan.Approved
RopinirolePipecuronium may increase the sedative activities of Ropinirole.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pipecuronium.Approved, Investigational
Secretin humanThe therapeutic efficacy of Human secretin can be decreased when used in combination with Pipecuronium.Approved
SeletracetamSeletracetam may increase the neuromuscular blocking activities of Pipecuronium.Investigational
SisomicinSisomicin may increase the respiratory depressant activities of Pipecuronium.Investigational
Sodium phosphate, monobasicThe therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Pipecuronium.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Solifenacin.Approved
SpironolactoneSpironolactone may increase the neuromuscular blocking activities of Pipecuronium.Approved
StreptomycinStreptomycin may increase the respiratory depressant activities of Pipecuronium.Approved, Vet Approved
SufentanilThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Sufentanil.Approved, Investigational
SulpiridePipecuronium may increase the anticholinergic activities of Sulpiride.Approved, Investigational
SumatriptanThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Sumatriptan.Approved, Investigational
TacrineThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Tacrine.Investigational, Withdrawn
TapentadolThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Tapentadol.Approved
TerodilineTerodiline may increase the neuromuscular blocking activities of Pipecuronium.Experimental
TetracyclineThe therapeutic efficacy of Pipecuronium can be increased when used in combination with Tetracycline.Approved, Vet Approved
TetrahydropalmatineTetrahydropalmatine may increase the neuromuscular blocking activities of Pipecuronium.Investigational
TetrandrineTetrandrine may increase the neuromuscular blocking activities of Pipecuronium.Experimental
TilidineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Tilidine.Experimental
TiotropiumPipecuronium may increase the anticholinergic activities of Tiotropium.Approved
TobramycinTobramycin may increase the respiratory depressant activities of Pipecuronium.Approved, Investigational
Tolfenamic AcidTolfenamic Acid may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Pipecuronium.Approved, Investigational
TopiramateThe risk or severity of hyperthermia and oligohydrosis can be increased when Pipecuronium is combined with Topiramate.Approved
TorasemideTorasemide may decrease the neuromuscular blocking activities of Pipecuronium.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Pipecuronium.Approved, Investigational
TranilastTranilast may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational
TrichlorfonThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideTrichlormethiazide may decrease the neuromuscular blocking activities of Pipecuronium.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Pipecuronium.Approved
TrimebutineTrimebutine may increase the neuromuscular blocking activities of Pipecuronium.Approved
TrimethadioneTrimethadione may increase the neuromuscular blocking activities of Pipecuronium.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Pipecuronium.Approved, Investigational
TropatepineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Tropatepine.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Pipecuronium.Approved, Investigational
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Pipecuronium.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Pipecuronium.Approved
TyrothricinThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Tyrothricin.Approved
UmeclidiniumPipecuronium may increase the anticholinergic activities of Umeclidinium.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Pipecuronium.Approved, Investigational
VancomycinThe therapeutic efficacy of Pipecuronium can be increased when used in combination with Vancomycin.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Pipecuronium.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Venlafaxine.Approved
VerapamilVerapamil may increase the neuromuscular blocking activities of Pipecuronium.Approved
VinpocetineVinpocetine may increase the neuromuscular blocking activities of Pipecuronium.Investigational
WIN 55212-2The risk or severity of Tachycardia and drowsiness can be increased when Pipecuronium is combined with WIN 55212-2.Experimental
ZiconotideZiconotide may increase the neuromuscular blocking activities of Pipecuronium.Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Zolmitriptan.Approved, Investigational
ZolpidemPipecuronium may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideZonisamide may increase the neuromuscular blocking activities of Pipecuronium.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0015431
KEGG Compound
C07554
PubChem Compound
50192
PubChem Substance
46508493
ChemSpider
45517
ChEBI
8230
ChEMBL
CHEMBL1201206
Therapeutic Targets Database
DAP000353
PharmGKB
PA164764567
Wikipedia
Pipecuronium
ATC Codes
M03AC06 — Pipecuronium bromide

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility9.5e-05 mg/mLALOGPS
logP-1.4ALOGPS
logP-5.3ChemAxon
logS-6.8ALOGPS
pKa (Strongest Basic)5.31ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area59.08 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity193.04 m3·mol-1ChemAxon
Polarizability72.22 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8906
Blood Brain Barrier+0.6351
Caco-2 permeable+0.5
P-glycoprotein substrateSubstrate0.8501
P-glycoprotein inhibitor IInhibitor0.7487
P-glycoprotein inhibitor IIInhibitor0.5983
Renal organic cation transporterNon-inhibitor0.7112
CYP450 2C9 substrateNon-substrate0.8587
CYP450 2D6 substrateNon-substrate0.7823
CYP450 3A4 substrateSubstrate0.7542
CYP450 1A2 substrateNon-inhibitor0.9065
CYP450 2C9 inhibitorNon-inhibitor0.9152
CYP450 2D6 inhibitorNon-inhibitor0.9059
CYP450 2C19 inhibitorNon-inhibitor0.8819
CYP450 3A4 inhibitorNon-inhibitor0.8232
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9438
Ames testNon AMES toxic0.752
CarcinogenicityNon-carcinogens0.9083
BiodegradationNot ready biodegradable0.9272
Rat acute toxicity2.6004 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9193
hERG inhibition (predictor II)Non-inhibitor0.7647
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as steroid esters. These are compounds containing a steroid moiety which bears a carboxylic acid ester group.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Steroid esters
Direct Parent
Steroid esters
Alternative Parents
Androstane steroids / N-methylpiperazines / Dicarboxylic acids and derivatives / Tetraalkylammonium salts / Trialkylamines / Carboxylic acid esters / Amino acids and derivatives / Azacyclic compounds / Organopnictogen compounds / Organic salts
show 4 more
Substituents
Steroid ester / Androstane-skeleton / N-methylpiperazine / N-alkylpiperazine / 1,4-diazinane / Dicarboxylic acid or derivatives / Piperazine / Tetraalkylammonium salt / Quaternary ammonium salt / Amino acid or derivatives
show 18 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
steroid ester (CHEBI:8230)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Drug binding
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name
CHRNA2
Uniprot ID
Q15822
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-2
Molecular Weight
59764.82 Da
References
  1. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  2. Karpati E, Biro K, Kukorelli T: [Investigation of neuromuscular blocking agents at Richter Ltd]. Acta Pharm Hung. 2002;72(1):37-48. [PubMed:12426786]
  3. Kiss JP, Windisch K, Balla A, Sershen H, Lajtha A: Dual effect of DMPP on the resting release of noradrenaline from rat hippocampal slices. Brain Res Bull. 1997;43(3):257-62. [PubMed:9227834]
  4. Torocsik A, Oberfrank F, Sershen H, Lajtha A, Nemesy K, Vizi ES: Characterization of somatodendritic neuronal nicotinic receptors located on the myenteric plexus. Eur J Pharmacol. 1991 Sep 24;202(3):297-302. [PubMed:1748153]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Karpati E, Biro K, Kukorelli T: [Investigation of neuromuscular blocking agents at Richter Ltd]. Acta Pharm Hung. 2002;72(1):37-48. [PubMed:12426786]
  2. Zappi L, Song P, Nicosia S, Nicosia F, Rehder K: Do pipecuronium and rocuronium affect human bronchial smooth muscle? Anesthesiology. 1999 Dec;91(6):1616-21. [PubMed:10598601]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. Karpati E, Biro K, Kukorelli T: [Investigation of neuromuscular blocking agents at Richter Ltd]. Acta Pharm Hung. 2002;72(1):37-48. [PubMed:12426786]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Identical protein binding
Specific Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Simon G, Biro K, Karpati E, Tuba Z: The effect of the steroid muscle relaxant pipecurium bromide on the acetylcholinesterase activity of red blood cells in vitro. Arzneimittelforschung. 1980;30(2a):360-3. [PubMed:6248079]

Drug created on June 30, 2007 12:08 / Updated on August 02, 2018 07:41